Effects of Preoperative Anti-TNF Therapy on Specimen Length in Crohn’s Disease and Beyond

Effects of Preoperative Anti-TNF Therapy on Specimen Length in Crohn’s Disease and Beyond

Bibliographic Details
Main Authors:	Marco Ettore Allaix, Andrea Resegotti, Mario Morino
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-06-01
Series:	Journal of Investigative Surgery
Online Access:	http://dx.doi.org/10.1080/08941939.2022.2048143

Similar Items

Preoperative Anti-TNF Therapy is Associated with a Shorter Length of Resected Bowel in Patients Undergoing Ileocolic Resection for Crohn’s Disease
by: Yuhua Huang, et al.
Published: (2022-06-01)

Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn’s Disease
by: Albert Boronat-Toscano, et al.
Published: (2022-09-01)

Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus
by: Ignacio Marin-Jimenez, et al.
Published: (2024-01-01)

MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
by: Gregor Jezernik, et al.
Published: (2023-02-01)

Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients
by: Elen Farinelli de Campos Silva, et al.
Published: (2018-10-01)

The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
by: Pazianas, M, et al.
Published: (2006)

Coexisting Crohn’s Disease and Takayasu’s Arteritis in Two Patients Treated with Anti-TNF-α Therapies
by: S. Ratuapli, et al.
Published: (2010-02-01)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
by: Paulo Gustavo Kotze, et al.
Published: (2017-04-01)

LAPAROSCOPIC ANTIREFLUX SURGERY: WERE OLD QUESTIONS ANSWERED? PARTIAL OR TOTAL FUNDOPLICATION?
by: Marco Ettore Allaix, et al.
Published: (2023-07-01)

Identification of Targets for Subsequent Treatment of Crohn’s Disease Patients After Failure of Anti-TNF Therapy
by: Yao Y, et al.
Published: (2023-10-01)

Anti‐TNFα induced lupus due to infliximab therapy in a patient with concurrent Crohn's disease
by: Akanksha Sharma, et al.
Published: (2023-07-01)

Landscape of sialylation patterns identify biomarkers for diagnosis and prediction of response to anti-TNF therapy in crohn’s disease
by: Chenglin Ye, et al.
Published: (2022-11-01)

Malignant melanoma in a patient with Crohn's disease and treated with anti-TNF alpha
by: Alfonso Alcalde Vargas, et al.
Published: (2013-12-01)

An Unusual Presentation of Tuberculosis in a Crohn’s Disease Patient Treated With Anti-TNF
by: Luísa Leite Barros, et al.
Published: (2022-01-01)

Targeting AQP9 enhanced the anti-TNF therapy response in Crohn's disease by inhibiting LPA-hippo pathway
by: Minhao Yu, et al.
Published: (2024-05-01)

Nutritional Biomarkers for the Prediction of Response to Anti-TNF-α Therapy in Crohn’s Disease: New Tools for New Approaches
by: Fernando Rizzello, et al.
Published: (2024-01-01)

Earlier anti-TNF therapy reduces the risk of malnutrition associated with alterations in body composition in patients with Crohn’s disease
by: Yuexin Wang, et al.
Published: (2023-02-01)

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
by: Kennedy, NA, et al.
Published: (2019)

Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
by: Maja Hanić, et al.
Published: (2023-06-01)

Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
by: Feldman, M, et al.
Published: (1998)

Anti-TNF therapy
by: Udalova, I, et al.
Published: (2016)

Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context
by: Hongsheng Yang, et al.
Published: (2023-12-01)

Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease
by: Chenglin Ye, et al.
Published: (2022-04-01)

Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease
by: Begoña Rodríguez Azor, et al.
Published: (2023-03-01)

A primary hepatic lymphoma in a patient with Crohn's disease receiving thiopurine and anti-TNF therapy: a case report
by: Salma Merhaben, et al.
Published: (2023-12-01)

PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
by: Paulo Gustavo KOTZE, et al.
Published: (2014-12-01)

Uncovering Novel Pre-Treatment Molecular Biomarkers for Anti-TNF Therapeutic Response in Patients with Crohn’s Disease
by: Min Seob Kwak, et al.
Published: (2022-03-01)

Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
by: Ivo Klarin
Published: (2023-01-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
by: Kira L. Newman, et al.
Published: (2023-03-01)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
by: Maini, R, et al.
Published: (1993)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
by: Rayer Cassandra, et al.
Published: (2022-12-01)

Development of a Prediction Model for Short-Term Remission of Patients with Crohn’s Disease Treated with Anti-TNF Drugs
by: Rosario Medina-Medina, et al.
Published: (2023-05-01)

Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn's perianal fistulas (PISA-II): long-term outcomes of an international, multicentre patient preference, randomised controlled trialResearch in context
by: Elise M. Meima - van Praag, et al.
Published: (2023-07-01)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
by: Cassandra Rayer, et al.
Published: (2023-02-01)

ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
by: Feldmann, M, et al.
Published: (2011)

Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn’s Disease Using Transcriptome Imputed from Genotypes
by: Soo Kyung Park, et al.
Published: (2022-06-01)

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
by: Chanchlani, N, et al.
Published: (2024)

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
by: Gi Hyeon Seo, et al.
Published: (2023-03-01)

Diet Advice for Crohn’s Disease: FODMAP and Beyond
by: Stefan L. Popa, et al.
Published: (2020-12-01)

Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
by: Gian Paolo Caviglia, et al.
Published: (2022-08-01)